RBC Capital Reiterates Buy Rating for GE HealthCare Technologies
RBC Capital maintains a Buy rating on GE HealthCare Technologies with a price target of $80, a 23.19% upside from the current price.
Key Points
- RBC Capital reiterated its Buy rating for GE HealthCare Technologies (NASDAQ:GEHC) with a price target of $80 on June 23, 2026.
- RBC Capital's $80 price target implies 23.19% upside from GE HealthCare Technologies Inc.'s ($GEHC) current $64.94 share price.
- Shares of GE HealthCare traded at $60.64 on Tuesday, with a market cap of approximately $27.58 billion and a P/E ratio of 14.54.
- Insiders have been active, with several buying and selling transactions in May 2026, while analysts maintain varied ratings with a consensus Buy.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
RBC Capital has reiterated its Buy rating for GE HealthCare Technologies Inc. (NASDAQ:GEHC) with a price target of $80. This announcement was made on June 23, 2026, and reflects continued confidence in the company's performance. Shares of GE HealthCare were trading at $60.64 on Tuesday.
RBC Capital vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
GE HealthCare Technologies Inc. Stock Down 9.5%
Shares of GE HealthCare Technologies traded at $60.64 on Tuesday. The company has a market cap of about $27.58 billion and a P/E ratio of 14.54. Its forward P/E is 11.31, and the stock has a beta of 0.862. Over the past year, its shares have ranged from a low of $58.75 to a high of $89.77. The 50-day moving average is $65.40, while the 200-day moving average is $74.64. The company maintains a current ratio of 1.22 and a quick ratio of 0.81, with a debt-to-equity ratio of 97.06.
$GEHC price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
GE HealthCare reported revenue of approximately $20.98 billion, with a revenue growth of 7.4%. The company's net margin stands at 9.1%, and it has a return on equity of 19.46%. Its earnings per share were $4.17. The next earnings report is expected on July 29, 2026.
Dividend
GE HealthCare pays an annual dividend rate of $0.14, yielding 0.23%. The payout ratio is a modest 4.2%.
Insider Buying and Selling at GE HealthCare Technologies Inc.
Several insiders have been active in trading GE HealthCare shares. On May 22, 2026, Kevin Lobo purchased 10,000 shares at an average price of $64.18. On May 15, Jeannette Bankes, CEO of Patient Care Solutions, sold 5,535 shares at $62.67. Philip Rackliffe, CEO of AIS, bought 16,458 shares on the same day. Other insiders, including Rodney Hochman, Phoebe Yang Watkin, and Lawrence Culp Jr., also made purchases in May.
Analysts Set New Price Targets
On June 23, 2026, RBC Capital reiterated its Buy rating for GE HealthCare with a price target of $80. UBS upgraded the stock to Hold with a $69 target on May 21. JP Morgan and Citigroup both maintained Hold ratings with a $65 target on April 30. Barclays maintained a Hold rating with a $78 target, while Evercore ISI Group and Wells Fargo maintained Buy ratings with targets of $80 and $75, respectively. The consensus among 18 analysts is a Buy rating, with a mean price target of $79.72.
About GE HealthCare Technologies
GE HealthCare Technologies Inc. develops and markets medical devices and digital solutions for diagnosis, treatment, and patient monitoring. It operates through four main segments: Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics. Headquartered in Chicago, Illinois, the company is led by CEO Peter J. Arduini and employs around 54,000 people.
Bottom Line
RBC Capital's reaffirmation of a Buy rating for GE HealthCare Technologies highlights ongoing confidence in the company's prospects. With a solid market position and diverse product offerings, GE HealthCare remains a significant player in the medical devices industry. Investors and analysts continue to track its performance, especially with the upcoming earnings report on July 29, 2026.
Get GE HealthCare Technologies Inc. alerts
New 13F filings, insider trades, and analyst moves on $GEHC, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.